If the Phase II results are positive, Palatin plans to advance to a larger Phase III trial in 2025
To further examine the cell surface specificity of LaccID, we performed promiscuous labeling with BP, enriched the biotinylated proteins with streptavidin beads and blotted the enriched material with antibodies against the endogenous ER marker calreticulin and the cell surface marker N-cadherin
Why Are Weight Loss Pills Making a Comeback
Regarding this concept, several nanocarriers have been developed to improve tumor-specific drug accumulation and controlled release process, including polymer-drug conjugates [96], dendrimers [157], nanogels [158], metallic nanoparticles [159], mesoporous silica nanoparticles [160], virus-like particles [161], lipid nanoparticles [162], and polymer nanoparticles [163]